Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Table 4 Difference in the 1/SCr versus time slope between run-in period (R0 ~ R20), and Treatment period (W4 ~ W28) analyzed by the ANCOVA model: comparison of the TRK-100STP groups versus placebo

Treatment group	No. of patients	Least square mean of the change in the 1/SCr slope		Difference in the least square mean (versus placebo)^a		Contrast test
		Least square mean of the change in the 1/SCr slope		Difference in the least square mean (versus placebo)^a		(P value)
		Point estimate	95 % CI	Point estimate	95 % CI	(−1,0,1)
Placebo	34	0.00516	[0.00187, 0.00845]	―	―
120 μg	32	0.01026	[0.00682, 0.01369]	0.00510	[0.00031, 0.00989]
240 μg	36	0.00798	[0.00478, 0.01118]	0.00282	[−0.00175, 0.00740]	0.2234

ISSN: 1471-2369